Multiple sclerosis Flashcards

1
Q

Immune-related response in which antibodies induce demyelination by antibody-dependent, cell-mediated cytotoxicity.
Cytokines attack myelin, macrophages help uptake myelin, oligodendrocyte apoptosis leads to an increase in demyelination, increased axonal injury occurs and becomes sclerosed.
-Inflammatory
-Demyelinating
-CNS- white matter in SC, brainstem, or cerebral hemispheres
-Plaques

A

Multiple Sclerosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Environmental risk factors for MS

A
  • Vitamin D deficiency (people living further from the equator have a greater risk)
  • smoking
  • infection (people w/ hx of Epstein-Barr virus or HHV-6 have greater risk)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Genetic risk factors for MS

A
  • First degree relative w/ MS

- Female > Male

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the most common age for MS diagnosis?

A

20-50

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Types of MS

A

Clinically isolated syndrome
Relapsing Remitting
Primary Progressive
Secondary Progressive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Clinically isolated syndrome

A
  • First episode of neuro symptoms that lasts at least 24 hours
  • Mono-focal lesion: single neurologic sign or symptom that’s caused by a single lesion
  • Multifocal lesion: more than one sign or symptom caused by lesions in more than one place
  • usually no association with fever or infection
  • followed by a complete or partial recovery
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Relapsing Remitting

A
  • Most common disease course
  • clearly defined attacks of new or increasing neurologic symptoms
  • increase in disability is confirmed when the person exhibits the same level of disability at the next scheduled neurological evaluation, typically 6-12 months later
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Primary progressive

A

-Worsening neurologic function from the onset of symptoms, without early relapses or remissions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Secondary progressive

A
  • follows initial relapsing-remitting course
  • most who are diagnosed with RRMS will eventually transition to secondary progressive worsening of neurologic function over time.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Activity of disease

A

Relapses or new increasing neurologic dysfunction, followed by full or potential recovery in the absence of fever or infection
(active or not active)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Progression of disease

A

steadily increasing neurologic dysfunction without recovery

progressive or not progressive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Traditional diagnosis of MS

A
  1. Evidence of damage in at least two separate areas of the CNS
  2. Evidence that the damage occurred at two distinct points in time, at least one month apart
  3. Other possible causes for the symptoms ruled out
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Revised diagnosis of MS

A

“In patients with a typical clinically isolated syndrome and clinical or MRI demonstration of dissemination in space, the presence of CSF-specific oligoclonal bands allows a diagnosis of Multiple Sclerosis”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Clinical features of MS

A
  • Optic neuritis (vision loss, pain w eye movement, usually unilateral)
  • brainstem/cerebellar dysfunction (ataxia, dysarthria, intention tremor, nystagmus, balance dysfunction)
  • pyramidal symptoms (UMN, paresthesia, spasticity, loss of dexterity)
  • spinal cord involvement (spasticity/flaccidity, sensory loss, motor loss, loss of bowel/bladder control)
  • fatigue(exacerbated by heat)
  • heat tolerance
  • cognitive dysfunction
  • depression
  • sexual dysfunction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Medical management of MS

A

Medications to…

  • modify disease course
  • manage relapses
  • manage symptoms
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Good prognosis of MS

A

Few attacks
good recovery from attacks
relapsing-remitting
early medical management and adherence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Poor prognosis of MS

A
multiple attacks
poor recovery from attacks
primary progressive type
pyramidal
brainstem
cerebellar signs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Prognosis is better depending on…

A

Gender (women > men)
Age of onset (< 35 at onset)
length between exacerbations (longer durations)
duration of impairments during exacerbation (shorter duration, < 1 month)
remission of initial impairments
only 1 impairment during the first year (fewer impairments early in dx)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Prognosis is worse depending on…

A

pyramidal tract impairments at onset
cerebellar impairments at onset
sphincter impairments at onset
progressive course at onset

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Possible impairments causing limitations in rolling and coming to sit

A

spasticity
timing & sequencing
central weakness
cerebellar ataxia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Possible impairments causing limitations in sitting balance

A
spasticity
timing &amp; sequencing of strategy
central weakness
cerebellar ataxia
sensory system impaired for strategies
inadequate vestibular function
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Possible impairments causing limitations in sit to stand

A
spasticity
timing &amp; sequencing of strategy
central weakness
cerebellar ataxia
sensory system impaired for strategies
inadequate vestibular function
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Possible impairments causing limitations in standing balance

A
spasticity
timing &amp; sequencing of strategy
central weakness
cerebellar ataxia
somatosensory impaired for reaction time
inadequate vestibular function
fatigue
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Possible impairments causing limitations in walking

A
spasticity
timing &amp; sequencing of strategy
central weakness
cerebellar ataxia
somatosensory impaired for reaction time
inadequate vestibular function
fatigue
25
Q

Possible impairments causing limitations in ADLs: grooming, bathing, cooking, feeding, etc.

A

UE central weakness

spasticity, timing & sequencing, ataxia, dysmetria, tremor, fatigue

26
Q

Most common problems in MS ranked

A
  1. fatigue
  2. walking and balance deficits
  3. bowel and bladder dysfunction
  4. pain/abnormal sensations
  5. visual disturbance
  6. cognitive dysfunction
  7. ataxia
27
Q

Acute fatigue

A

fatigue that has been present on >50% of the days or if there has been a significant development or increase of fatigue in the past 6 weeks, AND if fatigue is reported to limit functional activities or interfere with quality of life

28
Q

chronic fatigue

A

lasts longer than 6 weeks and is frequently present

29
Q

Recommended tool for measurement of fatigue in people with MS

A

MS edge: Modified Fatigue Impact Scale (MFIS)

30
Q

T/F: In ataxic gait, balance is typically less of an issue than lower limb incoordination

A

False.

In ataxic gait, balance (postural instability) may be more of an issue than lower limb incoordination.

31
Q

Recommended tool for measurement of gait in people with MS

A

Expanded Disability Status Scale (EDSS)
0.0-4.0 – able to walk without assistance
4.0-7.5 – primarily walking distance and assistance levels
6.0– walking with a cane
7.5-9.5 – main determinants are ability to transfer from w/c to bed and self-care
10 = death from MS

32
Q

MS EDGE recommendations for gait measurement

A
12-item MS walking scale
6MWT
DGI
TUG
Timed 25-foot walk
33
Q

MS-EDGE recommendations for balance measurement

A

Activities-specific balance confidence scale (ABC)
Berg Balance Scale
Functional Reach

34
Q

Presentation of Bladder and Bowel dysfunction in patient’s with MS

A

Bladder: most commonly, neurogenic overactive bladder.
-urgency, frequency, incontinence, difficulty emptying bladder
Bowel:
-constipation, involuntary loss of bowel control
can cause withdrawal, limited interpersonal relationships, UTIs, urinary retention, safety/fall risk

35
Q

Presentation of pain and abnormal sensation in patient’s with MS

A

headache
neuropathic extremity pain
low back pain
Lhermitte’s sign
trigeminal neuralgia
Pain is often from altered sensation: dysesthesia
hypersensitivity (allodynia, hyperalgesia)
sensory loss:
-spinal cord involvement – dermatomal
-brain involvement – homunculus distribution

36
Q

pain classifications

A
central neuropathic: 
-continuous (dysesthesia)
-intermittent (spontaneous, paroxysmal)
Non-neuropathic:
-musculoskeletal, LBP, HA's
-treatment induced
37
Q

presentation of weakness is people with MS

A
axonal damage
reduced/slowed force production
peripheral muscle fiber changes
disuse atrophy 
Test with MMT, dynamometry
38
Q

presentation of spasticity in pts with MS

A

Common in LE’s with MS
-flexor spasticity- hip and knee flexion, hamstring
-extensor spasticity- quads, adductors
interferes with activation, timing & sequencing
impairs gait and functional movement
can contribute to fatigue
Testing: modified Ashworth, Tardieu

39
Q

Presentation of cerebellar involvement in pt’s with MS

A
Ataxia
-dysdiadochokinesia-- timing of agonist/antagonist
-rebound-- delayed response
-dysmetria--amplitude problem
-dyssynergia-- sequencing problem
Intention tremor
Hypotonia
Vestibular inputs to cerebellum-balance
40
Q

How do you test disdiadochokinesia?

A
Rapid alternating pronation/supination (loses rhythm and range)
walk fast (gait impairment pronounced with increased speed)
41
Q

How do you test for rebound?

A

resist flexion of joint and let go (large movement of resisted limb when released)

42
Q

How do you test for dysmetria?

A

finger-to-nose, heel-to-shin
peg test
circle trace

43
Q

How do you test for Dyssynergia/decomposition of movement?

A
touch heel to opposite knee/hand to opposite elbow supine (movement slow and looks broken into phases)
dual task (worsens performance)
44
Q

How do you test for intention tremor?

A

Have patient move finger or foot toward your finger or a target (look for increased deviation from the path when the finger or foot approaches the target)

45
Q

How do you test for hypotonia?

A

passive limb movement (detect decreased resistance)
Muscle palpation (reduced firmness)
DTRs (decreased pendular swing with leg drop)
Hold object while conversing (drops object)

46
Q

What are the 3 direct predictors of participation limitations?

A
  1. Fatigue (most significant contributor)
  2. Physical Function
  3. Psychological variables
47
Q

MS-EDGE recommended measures for participation restrictions

A

Multiple Sclerosis Impact Scale (MSIS-29)
-physical scale (20 items)
-psychological scale (9 items)
Multiple Sclerosis Quality of Life (MS-QOL 54)
-12 sub-scales: physical function, role limitations-physical/emotional, pain, emotional well-being, energy, health perceptions, social function, cognitive function, health distress, overall quality of life, and sexual function

48
Q

What is important to remember about exercise and MS?

A
  • potential of elevated temperature to exacerbate weakness/fatigue
  • potential for medications to impact weakness/fatigue
  • decreased activity levels –> deconditioning/obesity
  • sleep disruptions could impact fatigue levels
  • depression
49
Q

overarching goals of PT for pt’s with MS

A
Help patient achieve/maintain optimal...
-functional independence
-safety
-quality of life
Provide resources for...
-equipment needs
-community support/programs
-education
50
Q

Keys for goal setting/treatment planning

A
Patient driven
Functional
Principle of task specificity 
provide rest intervals
avoid overheating
transition to home/community program
51
Q

Goal/interventions at diagnosis

A
education
connection with support systems
exercise/activity guidelines
fatigue issues
gait/balance or other impairments
follow up as needed
52
Q

Goals/interventions after relapse/attack

A

goal of returning to baseline function
may wait a couple weeks after onset to resume therapy
(could have new symptom, lack of sleep due to pain, etc.)

53
Q

Goals/interventions with progressive disease

A

avoid deconditioning
maximizing independent function
assessing for mobility aids

54
Q

Goals/interventions with advanced disease

A
seated trunk positioning/control
transfers
upper limb strength/function
respiratory function
equipment needs: standing devices can help with weight-bearing, stretching, b/b relief, respiration.
55
Q

Keys to successful compliance for HEPs

A

goal-oriented
meaningful
variable
enjoyable

56
Q

possible issues affecting compliance to HEPs

A

fatigue
depression
lack of support
cognitive function

57
Q

What can exercise improve for pts with MS?

A
aerobic and muscular fitness
fatigue
depression
walking
balance
cognition
QOL
sleep quality
exercise is also associated with: 
reduced rates of relapses
slowed disability progression
58
Q

Exercise guidelines for pts with MS

A

30 min of moderate intensity aerobic activity 2x/week
strength training exercises for major muscle groups 2x/week
*may reduce fatigue, improve mobility, and enhance elements of health-related quality of life